Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S1 plus Anlotinib in Refractory/Relapsed SCLC
NCT03823118Phase 2Completed
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- Mar 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and tegafur in small cell lung cancer (SCLC), sponsored by Taizhou Hospital of Zhejiang Province. Primary endpoints: Objective Response Rate up to 6 months and Progression-Free Survival up to 12 months. Started Mar 2019; status: completed.
02
Drugs
anlotinibtegafur
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03823118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03823118.